Preoperative Chemoradiation in Locally-Advanced Resectable Carcinoma of the Esophagus in a Single Rural Cancer Hospital in Western India

Yogesh S. Anap¹ Prasad K. Tanawade¹ Manish J. Mathankar¹ Ashwini D. Mane-Patil² Kiran G. Bagul³ Reshma S. Pawar³ Suraj B. Pawar³

¹Department of Radiation Oncology, Kolhapur Cancer Centre, Karveer, Maharashtra, India
²Department of Pathology, Kolhapur Cancer Centre, Karveer, Maharashtra, India
³Department of Surgical Oncology, Kolhapur Cancer Centre, Karveer, Maharashtra, India

Address for correspondence Dr. Yogesh S. Anap, MD, DNB, MNAMS, Department of Radiation Oncology, Kolhapur Cancer Centre, Karveer 416234, Maharashtra, India (e-mail: yogesh.anap1@gmail.com).

South Asian J Cancer 2020;9:158–162.

Abstract

Background The current standard of care for the treatment of surgically resectable carcinoma of the esophagus is preoperative chemoradiation followed by surgery. There is strong evidence that this trimodality approach improves survival as compared with surgery alone.

Objective The objective of this study is to determine the feasibility of this approach in a rural cancer institute in western India.

Materials and Methods The data of all the 157 consecutively treated patients with locally-advanced carcinoma of the esophagus from March 2013 to March 2017 who were started on preoperative chemoradiation were analyzed retrospectively.

Results Of the 157 patients who were started on preoperative chemoradiation, 68 patients underwent surgery. There are various practical reasons for not undergoing the definitive surgery, with the important being the socioeconomic support to the patients during the course of treatment.

Conclusion This study gave us insight into the strategic selection of patients for the trimodality approach as well as the need for continuous socioeconomic support throughout the treatment course.

Introduction

Esophageal carcinoma has the poor prognosis in spite of the advancement in treatment modalities. The incidence of newly diagnosed cases of carcinoma of the esophagus worldwide per year is 572,034, while the mortality is 508,585. The corresponding figures of India are 52,396 and 46,504, respectively.¹ The treatment has evolved from single modality to multimodality approach over the past few decades. Conventionally, esophagectomy has been the main choice of treatment for resectable middle and lower-third esophageal cancers. The trimodality approaches involving neoadjuvant chemoradiotherapy (NACRT) followed by surgery for resectable middle and lower-third esophageal cancer have been studied.² The feasibility of this combination treatment needs to be evaluated in developing countries, especially in the rural background. Here, we present an audit of the retrospective
analysis of prospectively maintained data of such combination treatment practiced in a single rural cancer center in Western India.

Materials and Methods

This is a retrospective study of 157 consecutive patients diagnosed with nonmetastatic carcinoma of the esophagus, and who were treated in a single cancer institute in rural Western India from March 2013 to March 2017. All case records and electronic data were retrieved and analyzed. All patients underwent endoscopic evaluation of the upper gastrointestinal tract (GIT). The disease was documented, and biopsies were collected. Patients underwent staging investigations with contrast-enhanced computed tomography (CT) scan of the neck, thorax and upper abdomen, and hematological counts for determining fitness for chemotherapy. All histology proven, treatment naïve cases of carcinoma of the middle and lower-third esophagus were included in the study. Histology other than squamous carcinoma and adenocarcinoma were excluded from the study. Patients with only localized disease with or without regional nodes were included. Patients with performance status 0, 1, and 2 and who would complete the intended neoadjuvant treatment were included for the treatment. All the patients carried out discussions with the surgical oncologist, radiation oncologist, and medical oncologist before initiating the treatment.

Treatment Details

Radiotherapy

The patient underwent neoadjuvant external radiotherapy to primary and regional nodes, with the help of photons, by conformal techniques such as either three-dimensional conformal radiation therapy (3DCRT) or intensity-modulated radiation therapy (IMRT) at doses of 41.4 Gy to 45 Gy in conventional fractionation over the duration of 5 weeks.

Chemotherapy

Patients received concomitant chemotherapy maximum of five cycles after ensuring adequate hematological and renal functions along with radiotherapy. The drugs received were either paclitaxel (50 mg/m²) with carboplatin (area under the curve = 2), cisplatin (30 mg/m²) with 5 fluorouracil (500 mg/m²), cisplatin (30 mg/m²) alone, or capcitabine (825 mg/m² BD) alone. The choice of chemotherapy was at the discretion of the treating oncologist.

Response Evaluation

Response to NACRT was evaluated with contrast-enhanced CT scan 4 to 5 weeks after NACRT, with response evaluation criteria in solid tumor criteria. Patients having complete response, partial response, or stable disease were evaluated for surgery. Patients with progression of disease underwent salvage treatment at the discretion of treating physician. Salvage treatment consisted of either completion of radiotherapy, chemotherapy, or best supportive care.

Surgery

Patients underwent esophagectomy, either open or thoracoscopic, 4 to 6 weeks after NACRT. All complications of surgery and histopathology were documented.

Follow-up and Evaluation

Patients were followed-up every 3 months for initial 2 years after completion of treatment and later at every 6 months. Disease status at each follow-up was documented.

Statistical Analysis

SPSS software version 21 was used for statistical analysis. Survival was calculated using the Kaplan–Meier method. Overall survival (OS) was calculated from the date of registration to the last date of follow-up or death. Disease-free survival was calculated from the date of surgery to the date of recurrence of the disease.

Results

One hundred and fifty-seven patients were started on NACRT. The demographic details were captured for all patients (~Table 1). The details of radiation therapy, chemotherapy, and surgery were documented (~Table 2). An effort was made to find the causes of default after neoadjuvant therapy through either telephonic contact with the patient or personal home visit by the hospital representative. The treatment-related toxicities and survival were captured (~Tables 3 and 4).

| Characteristics | Value | Absolute (%) |
|-----------------|-------|--------------|
| Study duration  | March 2013–March 2017 |
| Number of patients | 157 |
| Age (years), median (range) | 55 (30–81) |
| Gender          | Male 82 (52) |
| Category        | Private 27 (17) |
| Comorbidities   | Nil 107 (68) |
| Addictions      | Nil 62 (40) |
| Site            | Middle third 69 (44) |
| Histology       | Squamous carcinoma 136 (87) |
| T stage         | T2 5 (3) |
| N stage         | N0 52 (33) |
|                | N1 85 (54) |
|                | N2 20 (13) |
Discussion

The intention of this retrospective audit was to check the feasibility of NACRT followed by surgery in resectable carcinoma of the esophagus in a rural cancer center in western India.

Table 2  Treatment details

| Treatment details                  | Absolute number | Percentage |
|-----------------------------------|-----------------|------------|
| NART dose                         |                 |            |
| 45 Gy/25*                         | 136             | 87%        |
| 41.4 Gy/21*                       | 7               | 5%         |
| NART technique                    |                 |            |
| 3DCRT                             | 67              | 43%        |
| IMRT                              | 90              | 57%        |
| NART breaks                       |                 |            |
| Yes                               | 17              | 11%        |
| No                                | 140             | 89%        |
| Reasons for NART breaks           |                 |            |
| Machine breakdown                 | 4               | –          |
| Death                             | 2               | –          |
| Toxicity                          | 1               | –          |
| Default                           | 10              | –          |
| Concomitant CT given              |                 |            |
| Yes                               | 141             | 90%        |
| No                                | 16              | 10%        |
| Reason concomitant CT not given   |                 |            |
| Death                             | 2               | –          |
| Unfit                             | 2               | –          |
| Financial                         | 12              | –          |
| Concomitant CT drugs              |                 |            |
| P + C                             | 100             | –          |
| 5 FU + cisplatin                  | 16              | –          |
| Cisplatin                         | 3               | –          |
| Capecitabine                      | 22              | –          |
| Number of concomitant CT cycles, median | 5              | –          |
| Concomitant CT breaks             |                 |            |
| Yes                               | 50              | –          |
| No                                | 91              | –          |
| Concomitant CT breaks reasons     |                 |            |
| Toxicity                          | 41              | –          |
| Fitness                           | 2               | –          |
| Financial                         | 6               | –          |
| Communication gap                 | 1               | –          |
| Response CT scan done             |                 |            |
| Yes                               | 124             | –          |
| No                                | 33              | –          |
| Radiological response to NACRT    |                 |            |

(Continued)

Table 2 (Continued)

| Treatment details                  | Absolute numbers | Percentage |
|-----------------------------------|------------------|------------|
| Complete response                 | 1                | –          |
| Partial response                  | 86               | –          |
| Stable disease                    | 16               | –          |
| Progressive disease               | 21               | –          |
| Surgery done                      |                  |            |
| Yes                               | 68               | 43%        |
| No                                | 89               | 57%        |
| Reasons for no surgery            |                  |            |
| PD                                | 20               | –          |
| Financial                         | 39               | –          |
| Social                            | 6                | –          |
| Asymptomatic (patient’s decision) | 9                | –          |
| Unfit                             | 6                | –          |
| Death                             | 5                | –          |
| Unwilling for surgery             | 3                | –          |
| Second primary                    | 1                | –          |
| Duration between RT completion and surgery (days), median (range) | 49 (33–316) | – |
| Surgery type                      |                  |            |
| Thoracoscopic esophagectomy with 2-field lymphadenectomy | 36 | – |
| Thoracoscopic esophagectomy with 3-field lymphadenectomy | 6 | – |
| Transthoracic esophagectomy with 2-field lymphadenectomy | 9 | – |
| Transthoracic esophagectomy with 3-field lymphadenectomy | 8 | – |
| Transhiatal esophagectomy         | 9                | –          |

Abbreviations: 3DCRT, three-dimensional conformal radiation therapy; CT, computed tomography; FU, fluorouracil; IMRT, Intensity-modulated radiation therapy; NART, neoadjuvant radiotherapy; NACRT, neoadjuvant chemoradiotherapy; PD, progression of disease RT, radiotherapy.
We question the efficacy of this approach in the rural setting. We neither aim to prove the efficacy of this approach nor do we question the efficacy of this approach in the rural setting.

We want to highlight the practical problems that we faced in the implementation of this approach and the reasons for noncompliance to the treatment.

NACRT was tolerated well by all the patients with acceptable toxicity profile. The surgical complication rates were acceptable and less than reported in the literature.2

The practice at our institute till 2013 was upfront surgical resection, followed by adjuvant treatment for resectable carcinoma of the esophagus. The landmark randomized trial published in 2012 showed a significant OS benefit of 49.4 months in trimodality treatment versus 24 months in surgery alone arm.1 The “Evidence-Based Medicine Conference” conducted annually by the Tata Memorial Center, Mumbai, which discussed the guidelines for esophageal cancers in 2013 gave us the confidence to change our practice. We discussed the new strategy in our Institutional Review Board and started the new protocol from March 2013. Here, we present the retrospective audit of the patients afflicted with resectable carcinoma of the esophagus, and with curative intent, consecutively treated using NACRT. Fifty-six percent of the patients had carcinoma of the lower third of the esophagus; the most common histology was squamous cell carcinoma, in 87% of the patients, indicating squamous cell carcinoma is common histology even in the lower-third esophagus in our population. More than two-third of the patients were treated under one of the applicable government-sanctioned schemes, without any financial burden of the treatment on the patient or the family, but with certain limitations. The dose of radiotherapy for neoadjuvant setting in carcinoma of the esophagus varies in different randomized clinical trials. The range varies from 18.5 Gy to 50.4 Gy with different fractionation schedules.3-10 We implemented conventional fractionation schedules at doses of 41.4 Gy to 45 Gy with either 3DCRT or IMRT planning. The concomitant chemotherapy administered along with radiotherapy in neoadjuvant setting varies in different studies. The most commonly used drugs are cisplatin, 5 fluorouracil (5FU), paclitaxel, mitomycin, and etoposide.

Based on the CROSS trial results, we offered paclitaxel plus carboplatin regiment. However, due to financial reasons, this regimen was accepted by 72% of the patients. The rest received cisplatin or cisplatin with 5FU or capecitabine regimen. Sixteen patients received only neoadjuvant radiotherapy without concomitant chemotherapy, as they were unfit for chemotherapy. All the surgical specimens were reviewed by the single oncopathologist. There was no case with close or positive surgical cut margin in our group of patients. The pathological complete response rate was 40%, which is comparable with the published literature.1-10

The OS of patients who underwent the trimodality treatment and those who defaulted for surgery after neoadjuvant treatment was 18.5 months and 8 months, respectively, showing the obvious benefit of the completion surgery (Fig. 1).

Out of 89 patients who did not complete the intended treatment, 45 patients could have completed their intended treatment, provided necessary intervening measures would have been taken such as financial support and social support.

We neither aim to prove the efficacy of this approach nor do we question the efficacy of this approach in the rural setting.

### Table 3 Treatment-related toxicity details

| Toxicity               | Absolute numbers | Percentage |
|------------------------|------------------|------------|
| NART toxicity          |                  |            |
| Radiation dermatitis   |                  |            |
| Grade I                | 108              | 69         |
| Grade II               | 49               | 31         |
| Grade III-IV           | 0                | 0          |
| Esophagitis            |                  |            |
| Grade I                | 84               | 54         |
| Grade II               | 62               | 39         |
| Grade III              | 11               | 7          |
| CT toxicity (grade III)|                  |            |
| Anemia                 | 1                | 0.7        |
| Neutropenia            | 7                | 5          |
| Thrombocytopenia       | 1                | 0.7        |
| Renal                  | 15               | 11         |
| Significant surgical complications |               |            |
| Pulmonary              | 10               | 15         |
| VC palsy               | 8                | 12         |
| Death                  | 6                | 9          |
| Chyle leak             | 6                | 9          |
| Wound Infection        | 2                | 3          |

Abbreviations: CT, computed tomography; NART, neoadjuvant radiotherapy; VC, vocal cord.

### Table 4 Treatment outcome

| Treatment outcome                           | Value number |
|---------------------------------------------|--------------|
| Pathological response after surgery (%)     |              |
| Complete response                           | 27 (40)      |
| Partial response                            |              |
| OS in all patients (157 patients), months   | 41 (60)      |
| OS in patients who underwent surgery after neoadjuvant therapy (68 patients), months | 11 (1–63) |
| OS in patients who defaulted for surgery after neoadjuvant treatment (89 patients), months | 18.5 (3–63) |
| OS in patients who underwent surgery within 60 days of RT (51 patients), months | 8 (1–35) |
| OS of patients who underwent surgery after 60 days of RT (17 patients), months | 20 (3–63) |
| OS of patients who underwent surgery after 60 days of RT (17 patients), months | 17 (4–52) |
| DFS in all patients in surgery group (68 patients), months | 16.5 (3–62) |
| DFS in complete response group (27 months), months | 12 (3–62) |
| DFS in partial response group (41 patients), months | 15 (3–62) |

Abbreviations: DFS, disease-free survival; OS, overall survival; RT, radiotherapy.
The treating oncologist tried to contact all these patients through telephonic conversations or home visit by the representative. In spite of the treatment being partly or fully covered under government scheme, the priority of their daily wages prevented these patients from completing their treatment.

The next common reason for noncompliance was symptomatic relief due to neoadjuvant treatment in nine patients. Although the efforts were taken to stress the importance of surgery in spite of complete clinical benefit after neoadjuvant therapy, these patients never turned up for surgery.

Of the 20 patients who progressed after NACRT, 10 patients progressed at a distant site, while 10 patients progressed locally. These patients were advised palliative treatment or best supportive care.

This study gave us an insight into careful selection and counseling of the patients beforehand, ensuring lasting financial and social support through the course of the treatment in the rural setting in India. Interestingly, we found that the patients who underwent surgery within 60 days of completion of neoadjuvant treatment had a median overall survival of 20 months versus 17 months for those who came for surgery after 60 days. Majority of the delays in surgery was due to finances and logistics for surgery. This highlights the importance of adherence to the treatment schedule, especially after NACRT.

Conclusion

Our results for patients who completed the trimodality treatment are similar to those in the literature. However, the drop-out rate after NACRT was a matter of concern. This study gave us insight into the fact that trimodality treatment is feasible in rural India, provided the strategic selection of the patients and continuous socioeconomic support through the course of the treatment is ensured.

Financial Support and Sponsorship
Nil.

Conflicts of Interest
None declared.

References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424
2. Shapiro J, van Lanschot JJ, Hulshof MCC, et al; CROSS study group. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 2015;16(9):1090–1098
3. Urba SG, Orringer MB, Perez-Tamayo C, Bromberg J, Forastiere A. Concurrent preoperative chemotheraphy and radiation therapy in localized esophageal adenocarcinoma. Cancer 1992; 69(2):285–291
4. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335(7):462–467
5. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997; 337(3):161–167
6. Burmeister BH, Smithers BM, Gebski V, et al; Trans-Tasman Radiation Oncology Group; Australasian Gastro-Intestinal Trials Group. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 2005;6(9):659–668
7. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008;26(7):1086–1092
8. Stahl M, Stuschke M, Lehmann E, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005;23(10):2310–2317
9. Lee MS, MamonHJ, Hong TS, et al. Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer. Oncologist 2013;18(3):281–287
10. Krishnamurthy A, Mohanraj N, Radhakrishnan V, John A, Selvaluxmy G. Neoadjuvant chemoradiation for locally advanced resectable carcinoma of the esophagus: A single-center experience from India with a brief review of the literature. Indian J Cancer 2017;54(4):646–651